Reimpresión oficial de UpToDate ®

www.uptodate.com © 2023 UpToDate, Inc. y/o sus afiliados. Reservados todos los derechos.

Galantamina: Información de drogas

Copyright 1978-2023 Lexicomp, Inc. Todos los derechos reservados.

Divulgaciones de contribuyentes
(Para obtener información adicional, consulte "Galantamina: información sobre el medicamento para el paciente" )

Para consultar las definiciones de abreviaturas, símbolos y grupos de edad utilizados en Lexicomp ( ver tabla )

Nombres de marca: EE. UU.

Razadyne ER [DSC]; Razadyne [DSC]

Marcas comerciales: Canadá

APO-galantamina; auro-galantamina ER; Mar-galantamina ER [DSC]; MYLAN-galantamina ER;
PAT-galantamina ER; PMS-galantamina ER

Categoría farmacológica
Inhibidor de la acetilcolinesterasa (central)

Posología: Adulto
Collapse All

enfermedad de Alzheimer 

Enfermedad de Alzheimer, de leve a moderada:

Tableta o solución de liberación inmediata: Oral: Inicial: 4 mg dos veces al día

durante 4 semanas; si se tolera, aumente a 8 mg dos veces al día durante ≥4
semanas; si se tolera, aumente a 12 mg dos veces al día. Rango: 16 a 24 mg
diarios en 2 tomas divididas.

Cápsula de liberación prolongada: Oral: Inicial: 8 mg una vez al día durante 4

semanas; si se tolera, aumente a 16 mg una vez al día durante ≥4 semanas; si se
tolera, aumente a 24 mg una vez al día. Rango: 16 a 24 mg una vez al día.
 Nota: Si la terapia se interrumpe durante ≥3 días, reinicie con la dosis más baja y
aumente a la dosis actual.

Enfermedad de Alzheimer, grave (uso no indicado en la etiqueta): Oral: Tableta

de liberación inmediata: Inicial: 4 mg dos veces al día durante 4 semanas; si se
tolera, aumente a 8 mg dos veces al día durante ≥4 semanas; si se tolera, aumente a
12 mg dos veces al día. Puede reducirse a 8 mg dos veces al día si no se tolera la
dosis objetivo. Rango: 16 a 24 mg diarios en 2 tomas divididas ( Ref ).

Demencia con cuerpos de Lewy y demencia por enfermedad de Parkinson 

Demencia con cuerpos de Lewy y demencia por enfermedad de Parkinson (uso no

indicado en la etiqueta): Nota: en pacientes con demencia leve o moderada con
cuerpos de Lewy, considere la terapia con galantamina solo en pacientes que no toleran
el donepezilo y la rivastigmina ( Ref ).

Oral: La Asociación Estadounidense de Psiquiatría recomienda dosificación y

titulación similares a las de los pacientes con enfermedad de Alzheimer ( Ref ).

Demencia vascular, comórbida 

Demencia vascular, comorbilidad (uso fuera de etiqueta): Nota: Para uso en

pacientes con sospecha de enfermedad de Alzheimer comórbida, demencia por
enfermedad de Parkinson o demencia con cuerpos de Lewy ( Ref ).

Oral: Inicial: 4 mg dos veces al día durante 4 semanas; aumente a 8 mg dos

veces al día durante 4 semanas; si se tolera, aumente a 12 mg dos veces al día.
Rango: 16 a 24 mg/día en 2 tomas divididas ( Ref ).

Conversión de la formulación de liberación inmediata a la de liberación prolongada: los

pacientes pueden cambiar de la formulación de liberación inmediata a la de liberación
prolongada tomando la última dosis de liberación inmediata por la noche y comenzando la
dosis de liberación prolongada a la mañana siguiente; se debe utilizar la misma dosis diaria
total.

Conversión a galantamina de otros inhibidores de la colinesterasa: los pacientes que

experimentan una tolerabilidad deficiente con donepezil o rivastigmina deben esperar
hasta que desaparezcan los efectos secundarios o permitir un período de lavado de 7 días
 antes de comenzar con galantamina. Los pacientes que no experimentan efectos
secundarios con donepezilo o rivastigmina pueden comenzar la terapia con galantamina el
día inmediatamente posterior a la interrupción de la terapia anterior ( Ref ).

Ajuste de dosis para la terapia concomitante: Existen interacciones significativas entre

medicamentos, que requieren ajuste de dosis/frecuencia o evitación. Consulte la base de
datos de interacciones de medicamentos para obtener más información.

Dosificación: Insuficiencia renal: Adulto

Deterioro leve: No se proporcionan ajustes de dosis en la etiqueta del fabricante.

Moderate impairment (CrCl 9 to 59 mL/minute): Maximum dose: 16 mg/day.

Severe impairment (CrCl <9 mL/minute): Use is not recommended

Dosing: Hepatic Impairment: Adult

Mild impairment (Child-Pugh class A): There are no dosage adjustments provided in the
manufacturer’s labeling; however, single-dose galantamine pharmacokinetics were similar
to that observed in healthy subjects.

Moderate impairment (Child-Pugh class B): Maximum dose: 16 mg/day

Severe impairment (Child-Pugh class C): Use is not recommended

Dosing: Older Adult

Refer to adult dosing; adjust dose with caution in patients with low body weight and/or serious
comorbidities.

Adverse Reactions
The following adverse drug reactions and incidences are derived from product labeling unless
otherwise specified.

>10%: Gastrointestinal: Nausea (21%), vomiting (11%)

1% to 10%:

Cardiovascular: Bradycardia (1%), syncope (1%)

Endocrine & metabolic: Weight loss (5%)

Gastrointestinal: Abdominal distress (2%), abdominal pain (4%), decreased appetite

(7%), diarrhea (7%), dyspepsia (2%)
 Nervous system: Depression (4%), dizziness (8%), drowsiness (2%), falling (4%), fatigue
(4%), headache (7%), lethargy (1%), malaise (1%)

Neuromuscular & skeletal: Muscle spasm (1%), tremor (2%)

Miscellaneous: Laceration (1%)

<1%:

Cardiovascular: First degree atrioventricular block, flushing, hypotension, palpitations,

sinus bradycardia, supraventricular extrasystole

Dermatologic: Hyperhidrosis

Endocrine & metabolic: Dehydration

Gastrointestinal: Dysgeusia, retching

Nervous system: Hypersomnia, myasthenia, paresthesia

Ophthalmic: Blurred vision

Frequency not defined: Gastrointestinal: Anorexia

Postmarketing:

Cardiovascular: Complete atrioventricular block, hypertension

Dermatologic: Acute generalized exanthematous pustulosis, erythema multiforme, skin

rash, Stevens-Johnson syndrome

Hepatic: Hepatitis, increased liver enzymes

Hypersensitivity: Hypersensitivity reaction

Nervous system: Drug-induced extrapyramidal reaction, hallucination, seizure

Otic: Tinnitus

Contraindications
Hypersensitivity to galantamine or any component of the formulation.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to

other tertiary alkaloids.

Warnings/Precautions
Concerns related to adverse effects:

• CNS depression: May cause CNS depression, which may impair physical or mental
abilities; patients must be cautioned about performing tasks that require mental
alertness (eg, operating machinery or driving).

• Extrapyramidal effects: May exacerbate extrapyramidal symptoms due to an increase

in cholinergic tone.

• Skin reactions: Skin reactions including Stevens-Johnson syndrome, acute generalized

exanthematous pustulosis and erythema multiforme have been reported. Treatment
discontinuation may be necessary if skin reaction occurs; if rash is suspected to be
drug related, do not resume galantamine and consider alternative therapy.

• Vagotonic effects: Cholinesterase inhibitors may have vagotonic effects which may
cause bradycardia and/or heart block with or without a history of cardiac disease.

• Weight loss: Weight loss has been observed; monitor body weight.

Disease-related concerns:

• Cardiac conduction abnormalities: Use with caution in patients with sick-sinus

syndrome, bradycardia, or conduction abnormalities.

• Hepatic impairment: Use with caution in patients with mild to moderate liver
impairment; not recommended in severe impairment. Dose adjustment recommended
in moderate impairment.

• Peptic ulcer disease: Use with caution in patients at risk of ulcer disease (eg, previous
history or NSAID use); may increase gastric acid secretion. Monitor for symptoms of
bleeding.

• Renal impairment: Use with caution in patients with moderate renal impairment; not
recommended in severe impairment (CrCl <9 mL/minute).

• Respiratory disease: Use with caution in patients with COPD and/or asthma.

• Seizure disorder: Use with caution in patients with a history of seizure disorder.

• Urinary tract obstruction: Use with caution in patients with bladder outlet obstruction;
cholinomimetics may cause or worsen outflow obstructions.

Special populations:
 • Older adult: Limited safety data in patients ≥85 years of age. Use with caution
particularly in elderly patients with low body weight and/or serious comorbidities;
adjust dose with caution.

Dosage Forms: US
Excipient information presented when available (limited, particularly for generics); consult
specific product labeling. [DSC] = Discontinued product

Capsule Extended Release 24 Hour, Oral, as hydrobromide [strength expressed as base]:

Razadyne ER: 8 mg [DSC], 16 mg [DSC], 24 mg [DSC]

Generic: 8 mg, 16 mg, 24 mg

Solution, Oral, as hydrobromide:

Generic: 4 mg/mL (100 mL)

Tablet, Oral, as hydrobromide [strength expressed as base]:

Razadyne: 4 mg [DSC], 8 mg [DSC]

Razadyne: 12 mg [DSC] [contains fd&c yellow #6(sunset yellow)alumin lake]

Generic: 4 mg, 8 mg, 12 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsule ER 24 Hour Therapy Pack (Galantamine Hydrobromide ER Oral)

8 mg (per each): $6.10 - $6.36

16 mg (per each): $6.10 - $6.36

24 mg (per each): $6.10 - $6.36

Capsule ER 24 Hour Therapy Pack (Razadyne ER Oral)

8 mg (per each): $12.81

24 mg (per each): $12.81

Solution (Galantamine Hydrobromide Oral)

 4 mg/mL (per mL): $3.75

Tablets (Galantamine Hydrobromide Oral)

4 mg (per each): $3.18

8 mg (per each): $3.18

12 mg (per each): $3.18

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as
reference price only. A range is provided when more than one manufacturer's AWP price is
available and uses the low and high price reported by the manufacturers to determine the
range. The pricing data should be used for benchmarking purposes only, and as such should
not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or
considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly
disclaims all warranties of any kind or nature, whether express or implied, and assumes no
liability with respect to accuracy of price or price range data published in its solutions. In no
event shall Medi-Span be liable for special, indirect, incidental, or consequential damages
arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult
specific product labeling.

Capsule Extended Release 24 Hour, Oral, as hydrobromide [strength expressed as base]:

PAT-Galantamine ER: 8 mg, 16 mg, 24 mg

Generic: 8 mg, 16 mg, 24 mg

Tablet, Oral, as hydrobromide [strength expressed as base]:

Generic: 4 mg

Administration: Adult

Oral: Administer solution or tablet with breakfast and dinner; administer ER capsule with
breakfast. If therapy is interrupted for ≥3 days, restart at the lowest dose and increase to
current dose. If using oral solution, mix dose with 3 to 4 ounces of any nonalcoholic
beverage; mix well and drink immediately.
 Bariatric surgery: Capsule, extended release: Some institutions may have specific protocols
that conflict with these recommendations; refer to institutional protocols as appropriate.
No information available from manufacturer regarding safety of opening capsules.
Consider switching to IR tablets or oral solution.

Use: Labeled Indications

Alzheimer disease, mild to moderate: Treatment of mild to moderate dementia of Alzheimer
disease

Use: Off-Label: Adult

Alzheimer disease, severe; Dementia with Lewy bodies and Parkinson disease dementia;
Vascular dementia, comorbid

Medication Safety Issues

Sound-alike/look-alike issues:

Razadyne may be confused with Rozerem

International issues:

Reminyl [Canada and multiple international markets] may be confused with Amarel
brand name for glimepiride [France]; Amaryl brand name for glimepiride [US, Canada,
and multiple international markets]; Robinul brand name for glycopyrrolate [US and
multiple international markets].

Metabolism/Transport Effects
Substrate of CYP2D6 (minor), CYP3A4 (minor); Note: Assignment of Major/Minor substrate
status based on clinically relevant drug interaction potential

Drug Interactions
(For additional information: Launch drug interactions program)

Note: Interacting drugs may not be individually listed below if they are part of a group
interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a
complete list of drug interactions by individual drug name and detailed management
recommendations, use the Lexicomp drug interactions program by clicking on the “Launch
drug interactions program” link above.
Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of
Amifampridine. Amifampridine side effects may also be increased. Amifampridine may
enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase
inhibitor side effects may also be increased. Risk C: Monitor therapy

Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect

of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of
Acetylcholinesterase Inhibitors. Risk C: Monitor therapy

Antipsychotic Agents: Acetylcholinesterase Inhibitors (Central) may enhance the neurotoxic

(central) effect of Antipsychotic Agents. Severe extrapyramidal symptoms have occurred in
some patients. Risk C: Monitor therapy

Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of

Benoxinate. Specifically, the effects of benoxinate may be prolonged. Risk C: Monitor therapy

Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-

Blockers. Risk C: Monitor therapy

Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-

Causing Agents. Risk C: Monitor therapy

Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.

Management: If this combination cannot be avoided, monitor patients for evidence of
symptomatic bradycardia, and closely monitor blood pressure and heart rate during
therapy. Risk D: Consider therapy modification

Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect

of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased. Risk
C: Monitor therapy

Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase

Inhibitors. Increased muscular weakness may occur. Risk C: Monitor therapy

CYP2D6 Inhibitors (Strong): May increase the serum concentration of Galantamine. Risk C:
Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Galantamine. Risk C:
Monitor therapy

Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Risk C:

Monitor therapy
Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of
Fexinidazole. Risk X: Avoid combination

Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of

Fingolimod. Management: Consult with the prescriber of any bradycardia-causing agent to
see if the agent could be switched to an agent that does not cause bradycardia prior to
initiating fingolimod. If combined, perform continuous ECG monitoring after the first
fingolimod dose. Risk D: Consider therapy modification

Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine.

Risk C: Monitor therapy

Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of

Lacosamide. Risk C: Monitor therapy

Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C:

Monitor therapy

Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may

diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents
(Nondepolarizing). Risk C: Monitor therapy

Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C:

Monitor therapy

Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of

Ponesimod. Management: Avoid coadministration of ponesimod with drugs that may cause
bradycardia when possible. If combined, monitor heart rate closely and consider obtaining
a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less
than 55 bpm. Risk D: Consider therapy modification

Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.

Management: Avoid coadministration of siponimod with drugs that may cause bradycardia.
If combined, consider obtaining a cardiology consult regarding patient monitoring. Risk D:
Consider therapy modification

Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking

effect of Succinylcholine. Risk C: Monitor therapy

Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Risk C:

Monitor therapy
Pregnancy Considerations
Adverse events have been observed in animal reproduction studies.

Breastfeeding Considerations

It is not known if galantamine is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider
the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of
treatment to the mother.

Dietary Considerations
Administration with food is preferred, but not required; should be taken with breakfast and
dinner (tablet or solution) or with breakfast (capsule).

Monitoring Parameters
Mental status; body weight, symptoms of GI intolerance, symptoms of active or occult GI
bleeding

Mechanism of Action
Centrally-acting cholinesterase inhibitor (competitive and reversible). It elevates acetylcholine in
cerebral cortex by slowing the degradation of acetylcholine. Modulates nicotinic acetylcholine
receptor to increase acetylcholine from surviving presynaptic nerve terminals. May increase
glutamate and serotonin levels.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: 175 L

Protein binding: 18%

Metabolism: Hepatic metabolism primarily via CYP2D6 to O-desmethyl-galantamine and

3A4 to galantamine-N-oxide; the activity of galantamine metabolites is not considered to be
clinically relevant (Farlow 2003; Scott 2000)

Bioavailability: ~90%

Half-life elimination: ~7 hours

Time to peak: Immediate release: 1 hour (2.5 hours with food); extended release: 4.5-5
hours
 Excretion: Urine (20%)

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: AUC increased 37% and 67% in moderate and severe renal function
impairment.

Hepatic function impairment: Cl decreased about 25% in moderate (Child-Pugh score 7 to 9)

hepatic function impairment.

Older adult: Concentrations are about 30% to 40% higher.

Sex: Cl is about 20% lower in women than in men.

CYP2D6 poor metabolizers: There is an approximate 35% increase in AUC of unchanged

drug and 25% decrease in median Cl.

Brand Names: International

International Brand Names by Country 

For country code abbreviations ( show table)

(AE) United Arab Emirates: Reminyl; (AR) Argentina: Intelec er | Reminyl; (AT) Austria: Galantamin
actavis | Galantamin easypharm | Galantamin krka | Galantamin Ratiopharm | Galantamin sandoz |
Nivalin | Reminyl; (AU) Australia: Apo galantamine | Galantamine an | Galantyl | Gamine | Reminyl;
(BE) Belgium: Galantamine apotex | Galantamine eg | Galantamine mylan | Galantamine Sandoz |
Galantamine teva | Reminyl; (BG) Bulgaria: Galantagamma | Nivalin; (BR) Brazil: Bromidrato de
galantamina | Clometine | Cogit | Coglive | Elatium | Gaudy | Regressa | Reminyl; (CH) Switzerland:
Galantamin helvepharm | Reminyl; (CL) Chile: Galanvitae | Reminyl; (CN) China: Galanthamine
hydrobromide | Hui min | Jin kang ling li | Qi er neng | Shi wei bao; (CO) Colombia: Antamin |
Reminyl; (CZ) Czech Republic: Apo Galant | Galantamin mylan | Galantamin Teva | Reminyl; (DE)
Germany: Galanaxiro | Galantagamma | Galantamin | Galantamin 1A pharma | Galantamin Aaa |
Galantamin actavis | Galantamin AL | Galantamin CT | Galantamin glenmark | Galantamin heumann
| Galantamin Hexal | Galantamin hormosan | Galantamin Neurax | Galantamin Ratiopharm |
Galantamine mylan | Galnora | Nivalin | Reminyl; (DO) Dominican Republic: Reminyl; (EC) Ecuador:
Reminyl er; (EE) Estonia: Galsya | Reminyl; (EG) Egypt: Famalzyl | Reminyl; (ES) Spain: Galantamina
Actavis | Galantamina amneal | Galantamina Apotex | Galantamina cinfa | Galantamina combix |
Galantamina Kern | Galantamina Mylan | Galantamina normon | Galantamina Ratiopharm |
Galantamina Sandoz | Galantamina stada | Galantamina Teva | Galantamina tevagen | Galnora |
Reminyl; (FI) Finland: Galantamin actavis | Galantamin krka | Galantamin mylan | Galantamin orion |
Galantamin Stada | Galantamine teva | Reminyl; (FR) France: Galantamine | Galantamine Arrow |
Galantamine Biogaran | Galantamine cristers | Galantamine eg | Galantamine krka | Galantamine
mylan | Galantamine Sandoz | Galantamine teva | Galantamine Zydus | Reminyl | Reminyl LP; (GB)
United Kingdom: Acumor | Consion XL | Elmino xl | Gaalin | Galantamine | Galantex | Galsya |
Galzemic | Gatalin | Gazylan | Luventa | Reminyl | Zeebral XL; (GR) Greece: Galantamine |
 Galantamine /Pharmathen | Galanyl | Memo-Farmellas | Memoton Life | Micol raldex | Reminyl |
Zoroflog; (HK) Hong Kong: Reminyl; (ID) Indonesia: Reminyl; (IE) Ireland: Galsya | Reminyl; (IL) Israel:
Reminyl; (IN) India: Galamer | Galamer od; (IT) Italy: Galnora | Reminyl; (JO) Jordan: Reminyl; (JP)
Japan: Reminyl; (KR) Korea, Republic of: Galantamine | Galanyl Pr | Reminyl | Reminyl pr | Tamirin |
Tamirin sr; (KW) Kuwait: Reminyl; (LB) Lebanon: Reminyl; (LT) Lithuania: Galsya | Nivalin | Reminyl;
(LU) Luxembourg: Galantamine mylan | Reminyl; (LV) Latvia: Galsya | Nivalin; (MX) Mexico: Reminyl |
Reminyl er; (MY) Malaysia: Reminyl; (NL) Netherlands: Galantamine | Galantamine actavis |
Galantamine CF | Galantamine mylan | Galantamine Sandoz | Galantamine teva | Reminyl; (NO)
Norway: Galantamin krka | Reminyl; (NZ) New Zealand: Galantyl | Reminyl; (PE) Peru: Galanvitae sr |
Numencial | Reminyl; (PH) Philippines: Reminyl; (PK) Pakistan: Dementio | Dementio er | Reminyl; (PL)
Poland: Reminyl; (PR) Puerto Rico: Galantamine | Galantamine Hbr | Razadyne | Razadyne er; (PT)
Portugal: Galantamina | Galantamina Actavis | Galantamina Aurovitas | Galantamina ciclum |
Galantamina Generis | Galantamina Krka | Galantamina Labesfal | Galantamina Mylan |
Galantamina Ratiopharm | Galantamina Sandoz | Galantamina Teva | Galantamina Wynn |
Galantamina zentiva | Reminyl; (PY) Paraguay: Galantamina | Reminyl er; (RO) Romania: Galantamina
zentiva | Galsya | Reminyl; (RU) Russian Federation: Galantamin Teva | Galantamine | Galantamine
canon | Galnora sr | Nivalin | Reminyl; (SA) Saudi Arabia: Pms galantamine | Reminyl; (SE) Sweden:
Galantamin actavis | Galantamin krka | Galantamin mylan | Galantamin orion | Galantamin sandoz |
Galantamin Stada | Galantamin Teva | Indukolin | Reminyl; (SG) Singapore: Reminyl; (SI) Slovenia:
Galantamin Teva | Galsya | Gazylan | Reminyl; (SK) Slovakia: Galantamin mylan | Galantamin Teva |
Galsya | Reminyl; (TH) Thailand: Galantamine symgens | Reminyl; (TR) Turkey: Reminyl; (TW) Taiwan:
Reminyl; (UA) Ukraine: Reminyl; (UY) Uruguay: Galantamina normon | Galtamin | Reminyl; (VE)
Venezuela, Bolivarian Republic of: Proneurax; (ZA) South Africa: Remcept xl | Reminyl

Use of UpToDate is subject to the Terms of Use.

REFERENCES

1. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's
disease with dementia. Int J Geriatr Psychiatry. 2003;18(10):937-941. [PubMed 14533126]

2. APO-Galantamine (galantamine hydrobromide) [product monograph]. Weston, Ontario, Canada: Apotex Inc;
February 2023.

3. Auchus AP, Brashear HR, Salloway S, et al. Galantamine treatment of vascular dementia: a randomized trial.
Neurology. 2007;69(5):448-458. [PubMed 17664404]

4. Burns A, Bernabei R, Bullock R, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease
(the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol. 2009;8(1):39-47. [PubMed
19042161]

5. Chen YD, Zhang J, Wang Y, Yuan JL, Hu WL. Efficacy of cholinesterase inhibitors in vascular dementia: an updated
meta-analysis. Eur Neurol. 2016;75(3-4):132-141. [PubMed 26918649]

6. Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy
bodies: a 24-week open-label study. Dement Geriatr Cogn Disord. 2007;23(6):401-405. [PubMed 17409748]
 7. Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-1392. [PubMed
14674789]

8. Galantamine (galantamine hydrobromide oral solution, USP) [prescribing information]. Eatontown, NJ: West-Ward
Pharmaceuticals Corp; March 2020.

9. Galantamine (galantamine tablets, USP) [prescribing information]. Weston, FL: Apotex Corp; October 2020.
10. Hort J, O'Brien JT, Gainotti G, et al. EFNS Guidelines for the Diagnosis and Management of Alzheimer’s Disease. Eur
J Neurol. 2010;17(10):1236-1248. [PubMed 20831773]

11. Litvinenko IV, Odinak MM, Mogil'naya VI, et al. Efficacy and safety of galantamine (reminyl) for dementia in
patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol. 2008;38(9):937-945. [PubMed
18975103]

12. Morris JC, Farlow MR, Ferris SH, et al. Therapeutic Continuity in Alzheimer's Disease: Switching Patients to
Galantamine. Panel Discussion: Recommendations for Prescribers. Clin Ther. 2001;23(suppl A):31-39. [PubMed
11396870]

13. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for
people living with dementia and their carers. NICE guideline 97.
https://www.nice.org.uk/guidance/ng97/evidence/full-guideline-pdf-4852695709. Published June 2018. Accessed
March 31, 2021.

14. National Institute for Health and Care Excellence (NICE). Parkinson’s disease in adults. NICE guideline 71.
https://www.nice.org.uk/guidance/ng71/resources/parkinsons-disease-in-adults-pdf-1837629189061. Published
July 2017. Accessed March 30, 2021.

15. O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus
statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31(2):147-168.
[PubMed 28103749]

16. PAT-galantamine ER (galantamine extended-release) [product monograph]. Toronto, Ontario, Canada: Janssen
Inc; June 2021.

17. Rabins PV, Blacker D, Rovner BW, et al; APA Work Group on Alzheimer's Disease and other Dementias; Steering
Committee on Practice Guidelines. American Psychiatric Association practice guideline for the treatment of
patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry. 2007;164(12)(suppl):5-56.
[PubMed 18340692]

18. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month Randomized, Placebo-Controlled Trial With
a 6-month Extension. The Galantamine USA-1 Study Group, Neurology, 2000;54(12):2261-2268. [PubMed
10881250]

19. Razadyne and Razadyne ER (galantamine) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc;
October 2022.

20. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000;60(5):1095-1122. [PubMed
11129124]

21. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, Randomized, Placebo-controlled Trial of Galantamine in AD.
The Galantamine USA-10 Study Group. Neurology. 2000;54(12):2269-2276. [PubMed 10881251]
Topic 8739 Version 325.0